Scarica l'app Stockscreener
301.90
0.81%
-2.46
Pre-mercato:
292.84
-9.06
-3.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$304.36
Aprire:
$301.71
Volume 24 ore:
452.50K
Relative Volume:
1.21
Capitalizzazione di mercato:
$8.08B
Reddito:
$2.59B
Utile/perdita netta:
$168.80M
Rapporto P/E:
49.70
EPS:
6.0748
Flusso di cassa netto:
$357.20M
1 W Prestazione:
+1.45%
1M Prestazione:
+6.89%
6M Prestazione:
-3.47%
1 anno Prestazione:
+22.52%
Intervallo 1D:
$300.16
$307.49
Intervallo di 1 settimana:
$294.42
$307.49
Portata 52W:
$236.73
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Nome
Bio Rad Laboratories Inc
Settore
Industria
Telefono
(510) 724-7000
Indirizzo
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
301.90 | 8.08B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
101.66 | 177.07B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
319.14 | 122.35B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.29 | 106.61B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
43.77 | 65.06B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.00 | 48.94B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-08-28 | Iniziato | Wells Fargo | Equal Weight |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-04-03 | Downgrade | Citigroup | Buy → Neutral |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-06-16 | Iniziato | Wells Fargo | Overweight |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-01-28 | Reiterato | Citigroup | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2018-10-17 | Iniziato | Goldman | Buy |
| 2018-09-20 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Downgrade | CL King | Buy → Neutral |
| 2017-07-13 | Iniziato | Wells Fargo | Outperform |
| 2017-06-28 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Hold |
| 2016-10-13 | Iniziato | CL King | Buy |
| 2015-05-06 | Reiterato | Jefferies | Buy |
| 2009-12-18 | Iniziato | Maxim Group | Buy |
| 2009-11-06 | Iniziato | Jefferies & Co | Buy |
| 2009-07-17 | Iniziato | Soleil | Buy |
| 2007-09-26 | Iniziato | Banc of America Sec | Buy |
| 2007-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mostra tutto
Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Risk Profile - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Price to earnings forward of Bio-Rad Laboratories, Inc. – BOATS:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
BIO Q1 2026 Earnings: EPS Falls Short of Expectations, Shares Edge LowerEPS Revision Trend - dars.gov.et
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
Bio-Rad Launches Vericheck ddPCR Kits Compatible with QX700 Platform for Biopharma Quality Control and Cell and Gene Therapy Workflows - Cambridge Network
Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth - Ad-hoc-news.de
BIOBio-Rad Laboratories Inc Volatility & Greeks - Finviz
Price to sales forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
BIO.B Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bio-Rad Laboratories outlines long-term growth drivers as life science demand evolves - Ad-hoc-news.de
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO.B Technical Analysis & Stock Price Forecast - Intellectia AI
Bio-Plex Pro Human Cytokine Assays from Bio-Radmultiplex panels for immune research - ad-hoc-news.de
Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued - Sahm
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Evaluating Growth Amidst Stable Price Movements - DirectorsTalk Interviews
Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449) - TradingView
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW) - TradingView
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad rises as life-science tools deal activity and activist interest appear to lift sentiment - Quiver Quantitative
Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO) - TradingView
Bio-Rad Laboratories Jumps 5.6% Amid Sector-Wide Rally - AlphaStreet
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - AOL.com
Bio Rad Laboratories Inc (BIOb) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Why Bio-Rad’s Bio-Plex Pro Human Cytokine Screening Panel still matters in the lab - ad-hoc-news.de
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story - Sahm
Bio Rad Laboratories Inc (BIOb) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIOb) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIOb) Institutional Confidence - TradingKey
Bio Rad Laboratories Inc (BIOb) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc Azioni (BIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):